Septerna, Inc. Common Stock (SEPN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Septerna, Inc. Common Stock (SEPN) has a cash flow conversion efficiency ratio of -0.068x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.63 Million) by net assets ($378.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SEPN market cap overview for the company's overall valuation and market capitalisation.
Septerna, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Septerna, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Septerna, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Septerna, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore earnings quality score of Septerna, Inc. Common Stock to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ral Yatirim Holding AS
IS:RALYH
|
0.230x |
|
Supreme Petrochem Limited
NSE:SPLPETRO
|
-0.019x |
|
Republic Bancorp Inc
NASDAQ:RBCAA
|
0.063x |
|
Mineros SA
TO:MSA
|
0.098x |
|
ORG Packaging Co Ltd
SHE:002701
|
0.066x |
|
Sirius Real Estate Ltd
JSE:SRE
|
0.019x |
|
Clover Health Investments Corp
NASDAQ:CLOV
|
0.318x |
|
Jiangsu Huahong Technology Co Ltd
SHE:002645
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Septerna, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Septerna, Inc. Common Stock from 2022 to 2025. View today's stock price for Septerna, Inc. Common Stock for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $381.93 Million | $110.19 Million | 0.289x | +279.62% |
| 2024-12-31 | $420.05 Million | $-67.47 Million | -0.161x | -115.92% |
| 2023-12-31 | $-38.37 Million | $-38.72 Million | 1.009x | +91.40% |
| 2022-12-31 | $-44.20 Million | $-23.30 Million | 0.527x | -- |
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more